Acta Scientific Pharmaceutical Sciences (ASPS)(ISSN: 2581-5423)

Research Article Volume 4 Issue 12

Dysglycemic Effect and Misuse Prevalence of Fluoroquinolones in ICU Diabetic Patients

Rasha Ashmawy1*, Jayda M Ahmed2, Ingie A E El Chennawi3, George N Anis3, Logine A El Shaarawy3, Poula Azziz3, Aly El-halfawy3, Abdelrhman Agamy3, Amr Y Bargal3, Maged E Ahmed3, Nayera H Fouda3 and Ahmed R Farag3

1B. Pharm, MSc Biostatistics, Medical Research Institute, Alexandria University, Egypt
2Supervisor and Demonstrator at Department of Pharmacy Practice, Faculty of Pharmacy, Alexandria University, Egypt
3Students at Clinical Pharmacy Program, Faculty of Pharmacy, Alexandria University, Egypt

*Corresponding Author: Rasha Ashmawy, B. Pharm, MSc Biostatistics, Medical Research Institute, Alexandria University, Egypt.

Received: October 13, 2020; Published: November 18, 2020



Introduction: Quinolones are one of the most favourable antimicrobial class for the treatment of various infectious diseases. Their side effects and toxicity profile have been established years ago. Multiple studies reported dysglycemic events occurring in diabetic patients admitted to the ICU taking fluoroquinolones. The aim of this study is to determine if there is indeed a relation between fluoroquinolones and dysglycemia.

Methods and Materials: A retrospective observational study targeting the ICU patients who were administered levofloxacin, ciprofloxacin, and moxifloxacin. This study was performed during the period from April 2019 to September 2019 (6 months) in 5 different hospitals in Alexandria, Egypt. 350 patients’ ICU files were chosen randomly, then a total of 68 diabetic ICU admitted patients receiving broad-spectrum fluoroquinolones for more than 2 days were included in the study.

Results: From 68 patients who recruited in our study, 15 patients take fluoroquinolone with no need and they suffer from change in their blood glucose level without any additional benefit. The most misused fluoroquinolone was Levofloxacin, as 73.3% of patients with main diagnosis non-infectious treated with Levofloxacin, and 20% among them suffered from decreased blood glucose level where 13.3 % had significant increase of their blood sugar level.

Conclusion: Dysglycemia caused by fluoroquinolones is an important issue of clinical significance and must be addressed and managed. Dysglycemia occurs by varying degrees and differ between different agents of fluoroquinolones. The effect is more pronounced in diabetics and patients with renal impairment which warrant attention and immediate management. Fluoroquinolone misuse is also another important issue to be addressed as it contributes to increased antimicrobial resistance and exposes the patients to unnecessary side effects some of which might need immediate intervention. Further investigations related to fluoroquinolones prescribing and monitoring is needed to get a better understanding of this existing problem.

Keywords: Anti-infective(s); Fluoroquinolones; Toxicity; Dysglycemia; Adverse Events; Misuse; Diabetes



  1. Bambeke F Van., et al. “Quinolones in 2005: An Update”. European Society of Clinical Infectious Diseases4 (2005): 256-280.
  2. Emami Saeed., et al. “Quinolones: Recent Structural and Clinical Developments”. Iranian Journal of Pharmaceutical Research (2005): 123-136.
  3. Andriole Vincent T. “The Quinolones: Past, Present, and Future”. 41.2 (2005): 113-119.
  4. A ODonnell Judith and Steven P Gelone. “FLUOROQUINOLONES”. Infectious Disease Clinics of North America 2 (2000): 489-513.
  5. Rubinstein Ethan. History of Quinolones and Their 47.3 (2001): 3-8.
  6. Lipsky Benjamin A and Catherine A Baker. “Fluoroquinolone Toxicity Profiles: A Review Focusing on Newer Agent”. Clinical Infection Disease2 (1999): 352-364.
  7. Sarro Angela De and Giovambattista De Sarro. “Adverse Reactions to Fluoroquinolones. An Overview on Mechanistic Aspects”. Current Medicinal Chemistry (2001): 371-384.
  8. Owens, Robert C and D Pharm. “A Tale of Two Toxicities”. 25.10 (2005): 1291-1295.
  9. ZVONAR ROSEMARY. “Gatifloxacin-Induced Dysglycemia”. American Journal of Health-System Pharmacy 21 (2006): 2087-2092.
  10. Stumpo Carmine., et al. “Outpatient Gatifloxacin Therapy and Dysglycemia in Older Adults”. The New England Journal of Medicine 354 (2006): 1352-1361.
  11. Hatton Randy C. “An Evaluation of the Effects of Gatifloxacin on Glucose Homeostasis”. Pharmacy World and Science5 (2008): 544-549.
  12. Aspinall Sherrie L., et al. “Severe Dysglycemia with the Fluoroquinolones: A Class Effect?” 60141 (2009).
  13. Ghandour Sarah El and Sami T Azar. “Dysglycemia Associated with Quinolones”. Primary Care Diabetes 3 (2014): 168-171.
  14. Pharm, D., et al. “A Retrospective, Comparative Evaluation of Dysglycemias in Hospitalized Patients Receiving Gatifloxacin, Levofloxacin, Ciprofloxacin, or Ceftriaxone”. 25.10 (2005): 1303-1309.
  15. Singh Madhurita., et al. “Fatal Hypoglycemia with Levofloxacin Use in an Elderly Patient in the Post-Operative Periods”. Langenbecks Archives of Surgery2 (2008): 235-238.
  16. Kapoor Rajan., et al. “Life-Threatening Hypoglycemia With Moxifloxacin in a Dialysis Patient”. Journal of Clinical Pharmacology 2 (2012): 269-271.
  17. Laplante Kerry L., et al. “Prevalence of and Risk Factors for Dysglycemia in Patients Receiving Gatifloxacin and Levofloxacin in an Outpatient Setting” (2008).
  18. Stolz Randall R., et al. “Effect of Multiple-Dose Gatifloxacin or Ciprofloxacin on Glucose Homeostasis and Insulin Production in Patients with Noninsulin-Dependent Diabetes Mellitus Maintained with Diet and Exercise”. Pharmacotherapy 20 (2000): 76-86.
  19. Chou Hsu-wen., et al. “Risk of Severe Dysglycemia Among Diabetic Patients Receiving Levo Fl Oxacin, Cipro Fl Oxacin, or Moxi Fl Oxacin in Taiwan”. Clinical Infection Disease7 (2013): 971-98.
  20. Whiteley M., et al. “Hypoglycaemia in a Diabetic Patient, Associated with Ciprofloxacin Therapy”. Practical Diabetes International7 (1993): 50.
  21. Parilo Miguel. “Gatifloxacin-Associated Hypoglycemia”. (2002): 2-3.
  22. Jose J., et al. “Dysglycemia Associated With The Use Of Fluoroquinolones- Focus On Gatifloxacin. Review Article”. Wilderness and Environmental Medicine1 (2014): 114.
  23. Saraya Atsunori., et al. “Effects of Fluoroquinolones on Insulin Secretion and h -Cell ATP-Sensitive K + Channels”. 497 (2004): 111-117.
  24. Iguchi, A. “Increase in Insulin”. (1996): 372-76.
  25. Seligman B G S., et al. “Critical Steps in Fluoroquinolones and Carbapenems Prescriptions: Results from a Prospective Clinical Audit”. International Journal of Clinical Practice1 (2007): 147-152.
  26. Werner Nicole L., et al. “Unnecessary Use of Fluoroquinolone Antibiotics in Hospitalized Patients”. BMC Infectious Diseases 11 (2011).


Citation: Rasha Ashmawy., et al. “Dysglycemic Effect and Misuse Prevalence of Fluoroquinolones in ICU Diabetic Patients". Acta Scientific Pharmaceutical Sciences 4.12 (2020): 36-46.


Acceptance rate32%
Acceptance to publication20-30 days

Indexed In

News and Events

  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is April 30th, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue".
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US